NALFD in the Asia-Pacific region
The authors of the Lancet Gastroenterology & Hepatology Commission document here the burden of liver diseases in the Asia-Pacific region and formulate recommendations to tackle it.
Read More
NAFLD burden in Saudi Arabia and United Arab Emirates
In their article, K. Alswat et al. estimated NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and diabetes mellitus, in Saudi Arabia and United Arab Emirates.
Read MoreNALFD in the Asia-Pacific region
NAFLD burden in Saudi Arabia and United Arab Emirates
Machine learning-based approach to liver histology assessment
A. Taylor-Weiner et al. describe here a machine learning-based approach to liver histology assessment, which accurately characterises disease severity and heterogeneity, and sensitively quantifies treatment response in NASH.
Read More
Mechanisms, screening, prevention, and management of CVD in patients with NAFLD
Cardiovascular disease, rather than liver decompensation, remains the leading cause of morbidity and mortality in patients with NAFLD and NASH.
Read MoreMachine learning-based approach to liver histology assessment
Mechanisms, screening, prevention, and management of CVD in patients with NAFLD
Management of NAFLD in the Middle East
In a recent meta-analysis on the global epidemiology of NAFLD, Younossi et al. reported the prevalence to be highest (32%) in the Middle East.
Read More
Significant fatigue and pruritus are common in patients with advanced NASH
ZM Younossi et al. assessed the impact of fatigue and pruritus on patient-reported outcomes of patients with advanced NASH.
Read More